Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$7.44B+552.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gordon Naylor DipCompSc
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29,000
- Beta
- 0.08
- Country
- AU
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 6.63
Financials
Revenue
$7.44B+552.1%Net Income
$-2.99B-1642.6%EBITDA
$1.96B+494.1%Free Cash Flow
$1.87BEPS (diluted)
$-1.56-7223.3%Shares Outstanding (diluted)
1.92B-56.6%Operating Expenses
$1.74BCash & Debt
$1.51BReturn of Capital
$969.12MDividend per Share
$0.41Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $15.77B | $-2.59B | $-1.34 |
| 2025 | $15.43B | $3.00B | $0.39 |
| 2024 | $14.80B | $2.64B | $0.34 |
| 2023 | $13.17B | $2.19B | $0.28 |
| 2022 | $10.49B | $2.25B | $0.41 |
| 2021 | $10.27B | $1.78B | $0.33 |
| 2020 | $9.10B | $1.46B | $0.29 |
| 2019 | $8.54B | $1.92B | $0.27 |
| 2018 | $5.59B | $1.27B | $0.18 |
| 2017 | $5.06B | $1.02B | $0.18 |
| 2016 | $4.41B | $926.93M | $0.17 |
| 2015 | $4.15B | $1.05B | $0.18 |
| 2014 | $5.01B | $1.23B | $0.16 |
| 2013 | $4.58B | $1.21B | $0.14 |
Valuation
CSLLYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
123+146.67%Social Signal Score
Mentions (7)
- Newsproactiveinvestors.com·1d ago·Negative
CSL strikes US$1.6 billion licensing deal for rare disease drug CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting rare kidney and liver diseases. The deal gives CSL rights to advance the drug, which is currently in Phase 2 trials for ANCA-associated vasculitis, a rare autoimmune disease that can cause severe kidney damage.
View source ↗ - Newsreuters.com·1d ago·Negative
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.
View source ↗ - Newsprnewswire.com·1d ago·Negative
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to
View source ↗ - Newsreuters.com·7d ago·Neutral
Australia's CSL taps Amazon's cloud unit to boost research pipeline Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud arm to harness AI and cloud technology across its research and clinical development pipeline.
View source ↗ - Newsprnewswire.com·25d ago·Neutral
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.
View source ↗ - Newsseekingalpha.com·49d ago·Positive
CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
View source ↗ - Newsreuters.com·49d ago·Neutral
Australia's CSL reports 2% fall in annual profit Australia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
View source ↗
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$50,001 - $100,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Dec 29, 2018 (22d later)Sell$100,001 - $250,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 13, 2018 (13d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 13, 2018 (14d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 13, 2018 (440d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.